Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Eastern Cooperative Oncology Group
Dana-Farber Cancer Institute
R-Pharm
National Cancer Institute (NCI)
University of California, San Diego
Radiation Therapy Oncology Group
Merck Sharp & Dohme LLC
Incyte Corporation
Centre Antoine Lacassagne
BioAtla, Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
Commonwealth Healthcare Corporation
Nektar Therapeutics
Medical University of Vienna
University of Colorado, Denver
Washington University School of Medicine
University of Arizona
GlaxoSmithKline
The University of Texas Health Science Center at San Antonio
Washington University School of Medicine
Pfizer
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Groupe Oncologie Radiotherapie Tete et Cou
RTOG Foundation, Inc.
Bristol-Myers Squibb
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Presage Biosciences
Radiation Therapy Oncology Group
Arbeitsgemeinschaft medikamentoese Tumortherapie
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
University of Pittsburgh
Eisai Inc.
Glycotope GmbH
Bristol-Myers Squibb
University of Michigan Rogel Cancer Center
Washington University School of Medicine
University of Texas Southwestern Medical Center
UNC Lineberger Comprehensive Cancer Center
Groupe Oncologie Radiotherapie Tete et Cou
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
The Netherlands Cancer Institute
University of Colorado, Denver
Masonic Cancer Center, University of Minnesota
University of Pittsburgh